The trouble with translational medicine

Journal of Internal Medicine

Volumn 270, Issue 2, 2011, Pages 123-127

  Marincola, Francesco M ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Biomedical research; Clinical research; Translational medicine; Translational research

Indexed keywords

BIOLOGICAL MARKER; CANCER VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ARTICLE; CANCER IMMUNOTHERAPY; DISEASE MARKER; DRUG EFFICACY; FEEDBACK SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; NONHUMAN; PRIORITY JOURNAL; TRANSLATIONAL RESEARCH; VACCINATION; VACCINE FAILURE;

BIOMEDICAL RESEARCH; DRUG DISCOVERY; HUMANS; TRANSLATIONAL RESEARCH;

EID: 79960260495     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2011.02402.x     Document Type: Article

References (28)

1. Collins F. The bridge between lab and clinic. Nature 2010; 468: 877.
2. Lane J, Bertuzzi S. Research funding. Measuring the results of science investments. Science 2011; 331: 678-80.
3. Marincola FM. In support of descriptive studies: relevance to translational research. J Transl Med 2007; 5: 21.
4. Nussenblatt RB, Marincola FM, Schechter AN. Translational medicine - doing it backwards. J Transl Med 2010; 8: 12.
5. Hancock WW, Wang L, Ye Q, Han R, Lee I. Chemokines and their receptors as markers of allograft rejection and targets for immunosuppression. Curr Opin Immunol 2003; 15: 479-86.
6. Wang E, Worschech A, Marincola FM. The immunologic constant of rejection. Trends Immunol 2008; 29: 256-62.
7. Ena Wang, Francesco M Marincola, eds. Immunologic Signatures of Rejection. New York, NY: Springer, 2010.
8. Marincola FM. Translational medicine: a two way road. J Transl Med 2003; 1: 1.
9. Fontanarosa PB, DeAngelis CD. Basic science and translational research in JAMA. JAMA 2002; 287: 1728.
10. Ioannidis JP. Materializing research promises: opportunities, priorities and conflicts in translational medicine. J Transl Med 2004; 2: 5.
11. Sung NS, Crowley Jr WF, Genel M et al. Central challenges facing the national clinical research enterprise. JAMA 2003; 289: 1278-87.
12. Horig H, Marincola E, Marincola FM. Obstacles and opportunities in translational research. Nat Med 2005; 11: 705-8.
13. Littman BH, Di Mario L, Plebani M, Marincola FM. What's next in Translational Medicine? Clin Sci (Lond) 2007; 112: 217-27.
14. Marincola E. Why is public science education important? J Transl Med 2006; 4: 7.
15. Van EL, Marincola FM, Strohm J. Bridging the divide between science and journalism. J Transl Med 2010; 8: 25.
16. Salgaller ML, Marincola FM. Biotechnology entrepreneurship - where no research has gone before. J Transl Med 2010; 8: 102.
17. Davis MM. A prescription for human immunology. Immunity 2008; 29: 835-8.
18. Marincola FM. Future of immunotherapy: a call for comparative immunology. Immunotherapy 2009; 1: 1-3.
19. Louahed J, Grusell O, Gaulis S et al. Expression of defined genes indentifed by pre-treatment tumor profiling: association with clinical response to GSK MAGE A-3 immunetherapeutic in metastatic melanoma patients. J Clin Oncol 2008; 26: A9045.
20. Kirkwood JM, Ibrahim JG, Sosman JA et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001; 19: 2370-80.
21. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004; 10: 909-15.
22. Goldman B, DeFrancesco L. The cancer vaccine roller coaster. Nat Biotechnol 2009; 27: 129-39.
23. Wang E, Panelli MC, Marincola FM. Gene profiling of immune responses against tumors. Curr Opin Immunol 2005; 17: 423-7.
24. Wang E, Selleri S, Sabatino M et al. Spontaneous and tumor-induced cancer rejection in humans. Exp Opin Biol Ther 2008; 8: 337-49.
25. Wang E, Albini A, Stroncek DF, Marincola FM. New take on comparative immunology; relevance to immunotherapy. Immunotherapy 2009; 1: 355-66.
26. Wang E, Marincola FM. A natural history of melanoma: serial gene expression analysis. Immunol Today 2000; 21: 619-23.
27. Robertson L, Grip L, Mattsson HL, Hulthe J, Wiklund O. Release of protein as well as activity of MMP-9 from unstable atherosclerotic plaques during percutaneous coronary intervention. J Intern Med 2007; 262: 659-67.
28. Young NS, Ioannidis JP, Al-Ubaydli O. Why current publication practices may distort science. PLoS Med 2008; 5: e201.